ArticleInternational journal of endocrinology2026
Effects of Glucagon-Like Peptide-1 Receptor Agonist on Bone Metabolism and the Expression of Insulin Receptor Substrate 1 in an Osteoporotic Rat Model.
Article in International journal of endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effects of Glucagon-Like Peptide-1 Receptor Agonist on Bone Metabolism and the Expression of Insulin Receptor Substrate 1 in an Osteoporotic Rat Model.International journal of endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Study aim: This study aimed to investigate the effects of the GLP-1R agonist Exendin 4 on bone metabolism and insulin receptor Substrate 1 (IRS-1) expression in an osteoporotic (OP) rat model. Methods: Female SD rats were ovariectomized to establish an OP model. The rats ( Results: (1) The OVX + NS group showed a significant decrease in the number and thickness of trabeculae, fractured bone scaffold structure, and multiple adipocytes in the bone marrow cavity. Moreover, the trabeculae of the OVX + Exendin 4 group were increased in number and thickness. In addition, the bone scaffold structure was restored, and the bone marrow cavity showed fewer adipocytes than the OVX + NS group. And, the OVX + Exendin 4 group showed significantly increased BMD, BV/TV, Tb.Th, Tb.N, and bone biomechanical parameter levels ( Conclusion: Exendin 4 exerts its antiosteoporotic effects in OVX rats by improving BMD, restoring bone microstructures, elevating bone biomechanical parameter levels, decreasing bone turnover rate, and increasing the expression of IRS-1 in osteoblasts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.